Skip to main content
Jane Seagal

Jane Seagal

Vice President, Antibody Discovery, Ablexis and AlivaMab Biologics
Jane has over a decade of experience in antibody drug discovery using in vivo approaches. Prior to joining AlivaMab Biologics, Jane led the In Vivo Antibody Discovery team at AbbVie, where she introduced and implemented multiple technology platforms, including hybridoma automation and direct antibody cloning from human patient samples. Jane has led projects across diverse therapeutic areas and enabled antibody discovery campaigns resulting in several clinical candidate molecules